Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C1JV
|
|||
| Former ID |
DIB014582
|
|||
| Drug Name |
QGC-001
|
|||
| Synonyms |
QGC001
Click to Show/Hide
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Phase 2 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H20N2O6S4
|
|||
| Canonical SMILES |
C(CS(=O)(=O)O)C(CSSCC(CCS(=O)(=O)O)N)N
|
|||
| InChI |
1S/C8H20N2O6S4/c9-7(1-3-19(11,12)13)5-17-18-6-8(10)2-4-20(14,15)16/h7-8H,1-6,9-10H2,(H,11,12,13)(H,14,15,16)/t7-,8-/m0/s1
|
|||
| InChIKey |
HJPXZXVKLGEMGP-YUMQZZPRSA-N
|
|||
| CAS Number |
CAS 648927-86-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aspartyl aminopeptidase (DNPEP) | Target Info | Inhibitor | [2] |
| Glutamyl aminopeptidase (ENPEP) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Renin-angiotensin system | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02322450) Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of Quantum Genomics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.